A clinical study to evaluate the effect of Saptavarti Mahakalyanaka Ghrita in patients with anemia (Pandu disease).

An Open labelled, Active Controlled, Randomized, Clinical Trial to Evaluate the Effect of Saptavarti Mahakalyanaka Ghrita in the management of Pandu with special reference to Megaloblastic Anemia. - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/02/103146

Enrollment

Registered

2026-02-06

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D519- Vitamin B12 deficiency anemia, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patients belonging to the age group of 18 to 60 years of either gender irrespective of religion and socioeconomic status Patients already diagnosed with Pandu as well as newly diagnosed cases of Pandu Patients having serum vitamin B12 value less than 200 pg per mL Patients having hemoglobin levels below normal values that is less than 13 percent in men and less than 12 percent in women according to WHO criteria for nutritional anemia Patients having mean corpuscular volume value more than 100 femtoliter

Exclusion criteria

Exclusion criteria: Patients with a history of congenital disorders related to the haemopoietic system like SCA, leukaemia & haemophilia. Patients with a history of other systemic diseases, like uncontrolled diabetes mellitus. Patients suffering from disorders of the GIT system associated with gastrointestinal bleeding, like colorectal malignancy, peptic ulceration. Pregnant and lactating women. Immunocompromised Patients-HIV. Patients who are currently participating in any other clinical trials (in the last 2 months)

Design outcomes

Primary

Measure	Time frame
To evaluate the efficacy of Saptavarti Mahakalyanaka Ghrita in the management of Pandu with special reference to Megaloblastic Anemia.Timepoint: The primary outcome will be evaluated by comparing the mean change in serum Vitamin B12 levels and MCV values from baseline to Day 90 of treatment.	—

Secondary

Measure	Time frame
To evaluate the effect of Saptavarti Mahakalyanaka Ghrita based on the Fatigue assessment scaleTimepoint: On 1st visit and 6th visit	—

Countries

India

Contacts

Public ContactDR MANU R

Parul institute of ayurved

manu.r260022@paruluniversity.ac.in81608858967

Outcome results